Roxithromycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Roxithromycin: From Bacterial Infections to Leprosy
One-Sentence Summary
Roxithromycin is a macrolide antibiotic conventionally used to treat bacterial respiratory tract and skin/soft tissue infections. The TxGNN model predicts it may be effective for leprosy (Hansen’s disease), with 0 clinical trials and 5 publications — all preclinical/mechanistic — currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in Denmark; internationally used as a macrolide antibiotic for bacterial respiratory tract and skin/soft tissue infections |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for roxithromycin is not available from DrugBank. Based on known pharmacology, roxithromycin is a macrolide antibiotic (an erythromycin derivative) that inhibits bacterial protein synthesis by reversibly binding the 50S ribosomal subunit; its efficacy against a broad range of Gram-positive and some Gram-negative organisms, including atypical pathogens, is well established.
Leprosy is caused by Mycobacterium leprae, and macrolides as a class have documented direct antimycobacterial activity as well as anti-inflammatory and immunomodulatory effects — properties relevant both to bacterial clearance and to managing the peripheral neuropathy and inflammatory reactions seen in leprosy.
Supporting literature specifically shows roxithromycin has in vitro and in vivo (mouse footpad model) bactericidal activity against M. leprae, and is noted alongside clarithromycin, minocycline, and fosfomycin for combined antimycobacterial and anti-inflammatory/immunomodulatory action relevant to leprosy neuropathy management. This gives the TxGNN prediction a plausible mechanistic basis, though clarithromycin appears more potent than roxithromycin in head-to-head comparisons, and no clinical trial data in humans exists yet.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1648889 | 1991 | Preclinical (animal) | Antimicrobial Agents and Chemotherapy | Roxithromycin and clarithromycin, unlike erythromycin/azithromycin, were consistently bactericidal against M. leprae in mouse footpad infection; clarithromycin was superior |
| 3072920 | 1988 | Preclinical (in vitro/in vivo) | Antimicrobial Agents and Chemotherapy | Assessed relative in vitro activity of newer macrolides with favorable pharmacokinetics against M. leprae |
| 2665640 | 1989 | Preclinical (in vitro) | Antimicrobial Agents and Chemotherapy | Screened >25 antimicrobial agents, including roxithromycin, for antileprosy activity using macrophage-based phenolic glycolipid synthesis assay |
| 10481449 | 1999 | Mechanism/clinical commentary | Japanese Journal of Leprosy | Roxithromycin shown to have anti-M. leprae activity plus anti-inflammatory/immunomodulatory action relevant to control of leprous peripheral neuropathy |
| 12762831 | 2003 | Review | American Journal of Clinical Dermatology | General review of macrolide use and mechanism (ribosomal binding) in skin infections; not leprosy-specific |
Denmark Market Information
Roxithromycin currently has no marketing authorisation on record in Denmark (market status: not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Regulatory safety data (warnings, contraindications, drug interactions) for roxithromycin was not available in this evidence pack — this is flagged as a blocking data gap for safety evaluation (see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to preclinical/mechanistic studies (in vitro assays and mouse-model data from the late 1980s–1990s) with no completed or ongoing clinical trials in leprosy patients. A blocking data gap on TFDA/SmPC warnings and contraindications also prevents a preliminary safety assessment (S1).
To proceed, the following is needed:
- TFDA/SmPC safety label data (warnings, contraindications, drug interactions) to resolve the blocking data gap
- Confirmed mechanism-of-action data from DrugBank
- A modern proof-of-concept or comparative clinical study of roxithromycin (vs. established antileprosy regimens such as multidrug therapy) in leprosy patients, given existing preclinical data is decades old and clarithromycin has shown superior potency in the same animal model
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.